Literature DB >> 11141146

Drug Points: tachycardia associated with moxifloxacin.

M Siepmann1, W Kirch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11141146      PMCID： PMC26602          DOI： 10.1136/bmj.322.7277.23

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Safety profile of grepafloxacin compared with other fluoroquinolones.

Authors:  R Stahlmann; R Schwabe
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

Review 2.  Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.

Authors:  H Lode; F Vogel; W Elies
Journal:  Clin Ther       Date:  1999-01       Impact factor: 3.393

Review 3.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 4.  Toxicity of quinolone antimicrobial agents.

Authors:  S Takayama; M Hirohashi; M Kato; H Shimada
Journal:  J Toxicol Environ Health       Date:  1995-05

5.  Acute effects of flosequinan (BTS 49465) in untreated moderate to severe hypertension.

Authors:  M C Janssen; P Smits; J Reyenga; T Thien
Journal:  J Hum Hypertens       Date:  1995-05       Impact factor: 3.012
  5 in total
  2 in total

Review 1.  [Ventricular tachyarrhythmia as a side effect of pharmacotherapy].

Authors:  Thomas Demming; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-09

Review 2.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.